Sell 3/10/2025Downgrade
StageZero Life Sciences Ltd. (SZLSF) was downgraded to E+ from D- on 3/10/2025 due to a substantial decline in the valuation index and volatility index.

Sell 2/21/2025Upgraded
StageZero Life Sciences Ltd. (SZLSF) was upgraded to D- from E+ on 2/21/2025 due to an increase in the volatility index and growth index.

Sell 1/28/2025Downgrade
StageZero Life Sciences Ltd. (SZLSF) was downgraded to E+ from D- on 1/28/2025 due to a decline in the total return index and volatility index.

Sell 1/13/2025Upgraded
StageZero Life Sciences Ltd. (SZLSF) was upgraded to D- from E+ on 1/13/2025 due to an increase in the volatility index.

Sell 12/27/2024Downgrade
StageZero Life Sciences Ltd. (SZLSF) was downgraded to E+ from D- on 12/27/2024 due to a decline in the volatility index.

Sell 8/29/2024Upgraded
StageZero Life Sciences Ltd. (SZLSF) was upgraded to D- from E+ on 8/29/2024 due to an increase in the volatility index and valuation index.

Sell 3/14/2023Downgrade
StageZero Life Sciences Ltd. (SZLSF) was downgraded to E+ from D on 3/14/2023 due to a decline in the valuation index.

Sell 2/9/2023Upgraded
StageZero Life Sciences Ltd. (SZLSF) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.

Sell 2/8/2023Downgrade
StageZero Life Sciences Ltd. (SZLSF) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index.

Sell 11/21/2022Upgraded
StageZero Life Sciences Ltd. (SZLSF) was upgraded to D from D- on 11/21/2022 due to a substantial increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.0133 to -$0.0005, operating cash flow increased 87.26% from -$558.3 to -$71.1, and EBIT increased 30.7% from -$2.01M to -$1.39M.

Sell 10/27/2022Upgraded
StageZero Life Sciences Ltd. (SZLSF) was upgraded to D- from E+ on 10/27/2022 due to an increase in the volatility index.

Sell 10/12/2022Downgrade
StageZero Life Sciences Ltd. (SZLSF) was downgraded to E+ from D- on 10/12/2022 due to a decline in the volatility index and total return index.

Sell 9/21/2022Upgraded
StageZero Life Sciences Ltd. (SZLSF) was upgraded to D- from E+ on 9/21/2022 due to an increase in the valuation index, volatility index and total return index.

Sell 8/17/2022Downgrade
StageZero Life Sciences Ltd. (SZLSF) was downgraded to E+ from D- on 8/17/2022 due to a large decline in the growth index, solvency index and valuation index. Earnings per share declined from -$0.0063 to -$0.0133, debt to equity increased from 0.41 to 0.86, and the quick ratio declined from 0.18 to 0.03.

Sell 6/23/2022Downgrade
StageZero Life Sciences Ltd. (SZLSF) was downgraded to D- from D on 6/23/2022 due to a decline in the volatility index and total return index.

Sell 6/8/2022Upgraded
StageZero Life Sciences Ltd. (SZLSF) was upgraded to D from D- on 6/8/2022 due to an increase in the volatility index.

Sell 5/23/2022Downgrade
StageZero Life Sciences Ltd. (SZLSF) was downgraded to D- from D on 5/23/2022 due to a large decline in the solvency index, valuation index and volatility index. The quick ratio declined from 0.39 to 0.18.

Sell 5/17/2022Upgraded
StageZero Life Sciences Ltd. (SZLSF) was upgraded to D from E+ on 5/17/2022 due to an increase in the volatility index.

Sell 5/13/2022Downgrade
StageZero Life Sciences Ltd. (SZLSF) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and total return index.

Sell 5/4/2022Upgraded
StageZero Life Sciences Ltd. (SZLSF) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.

Sell 5/1/2022Downgrade
StageZero Life Sciences Ltd. (SZLSF) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index and total return index.

Sell 4/21/2022Upgraded
StageZero Life Sciences Ltd. (SZLSF) was upgraded to D from E+ on 04/21/2022.

Sell 4/20/2022Downgrade
StageZero Life Sciences Ltd. (SZLSF) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index.

Sell 4/18/2022Upgraded
StageZero Life Sciences Ltd. (SZLSF) was upgraded to D from D- on 4/18/2022 due to a noticeable increase in the growth index and valuation index. Total revenue increased 119.54% from $684.3 to $1.5M, and earnings per share increased from -$0.0334 to -$0.0275.

Sell 1/7/2022Downgrade
StageZero Life Sciences Ltd. (SZLSF) was downgraded to D- from D on 1/7/2022 due to a decline in the total return index and volatility index.

Sell 12/20/2021Upgraded
StageZero Life Sciences Ltd. (SZLSF) was upgraded to D from D- on 12/20/2021 due to an increase in the total return index and valuation index.

Sell 11/29/2021Downgrade
StageZero Life Sciences Ltd. (SZLSF) was downgraded to D- from D on 11/29/2021 due to a decline in the total return index and volatility index.

Sell 11/12/2021Upgraded
StageZero Life Sciences Ltd. (SZLSF) was upgraded to D from E+ on 11/12/2021 due to an increase in the total return index and valuation index.

Sell 11/8/2021Downgrade
StageZero Life Sciences Ltd. (SZLSF) was downgraded to E+ from D on 11/8/2021 due to a decline in the total return index.

Sell 11/3/2021Upgraded
StageZero Life Sciences Ltd. (SZLSF) was upgraded to D from D- on 11/3/2021 due to an increase in the valuation index and total return index.

Sell 10/8/2021Downgrade
StageZero Life Sciences Ltd. (SZLSF) was downgraded to D- from D on 10/8/2021 due to a substantial decline in the total return index, growth index and volatility index. EBIT declined 985.67% from -$215.7 to -$2.34M, operating cash flow declined 123.59% from -$1.1M to -$2.45M, and total revenue declined 83.66% from $2.48M to $404.7.

Sell 11/20/2020Downgrade
StageZero Life Sciences Ltd. (GNWSF) was downgraded to D from C on 11/20/2020 due to a significant decline in the valuation index, efficiency index and solvency index. Net income declined 2,697.82% from $178.8 to -$4.64M, total capital declined 269.03% from -$1.33M to -$4.9M, and the quick ratio declined from 0.62 to 0.34.

Hold 10/2/2020Upgraded
StageZero Life Sciences Ltd. (GNWSD) was upgraded to C from C- on 10/2/2020 due to a significant increase in the valuation index and volatility index.

Hold 9/17/2020Downgrade
StageZero Life Sciences Ltd. (GNWSF) was downgraded to C- from C on 9/17/2020 due to a significant decline in the valuation index and volatility index.

Hold 8/19/2020Upgraded
StageZero Life Sciences Ltd. (GNWSF) was upgraded to C from D on 8/19/2020 due to a significant increase in the valuation index, efficiency index and solvency index. The quick ratio increased from 0.04 to 0.62, net income increased 106.62% from -$2.7M to $178.8, and total capital increased 64.08% from -$3.7M to -$1.33M.

Sell 5/1/2020Downgrade
StageZero Life Sciences Ltd. (GNWSF) was downgraded to D from D+ on 5/1/2020 due to a significant decline in the efficiency index, solvency index and valuation index.

Sell 3/30/2020Upgraded
StageZero Life Sciences Ltd. (GNWSF) was upgraded to D+ from D on 3/30/2020 due to an increase in the volatility index.

Sell 2/25/2020Downgrade
StageZero Life Sciences Ltd. (GNWSF) was downgraded to D from D+ on 2/25/2020 due to a decline in the total return index.

Sell 2/5/2020Upgraded
StageZero Life Sciences Ltd. (GNWSF) was upgraded to D+ from D on 2/5/2020 due to an increase in the total return index and growth index.

Sell 1/13/2020Downgrade
StageZero Life Sciences Ltd. (GNWSF) was downgraded to D from D+ on 1/13/2020 due to a decline in the total return index and growth index.

Sell 12/27/2019Upgraded
StageZero Life Sciences Ltd. (GNWSF) was upgraded to D+ from D on 12/27/2019 due to an increase in the total return index.

Sell 11/27/2019Downgrade
StageZero Life Sciences Ltd. (GNWSF) was downgraded to D from D+ on 11/27/2019 due to a large decline in the growth index, efficiency index and total return index. Operating cash flow declined 617.84% from -$395.2 to -$2.84M, and EBIT declined 5.43% from -$1.37M to -$1.45M.

Sell 11/6/2019Downgrade
StageZero Life Sciences Ltd. (GNWSF) was downgraded to D+ from C- on 11/6/2019 due to a decline in the total return index, volatility index and solvency index. Debt to equity increased from -0.34 to -0.32.

Hold 6/12/2019Upgraded
GeneNews Limited (GNWSF) was upgraded to C- from D+ on 6/12/2019 due to an increase in the total return index and volatility index.

Sell 5/28/2019Downgrade
GeneNews Limited (GNWSF) was downgraded to D+ from C- on 5/28/2019 due to a noticeable decline in the growth index, total return index and solvency index. Earnings per share declined from -$0.0004 to -$0.05, operating cash flow declined 108.66% from -$453.7 to -$946.7, and debt to equity increased from -0.67 to -0.42.

Hold 4/4/2019Upgraded
GeneNews Limited (GNWSF) was upgraded to C- from D+ on 4/4/2019 due to a large increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.0051 to -$0.0005, operating cash flow increased 40.79% from -$766.2 to -$453.7, and EBIT increased 10.29% from -$1.13M to -$1.01M.

Sell 2/21/2019Upgraded
GeneNews Limited (GNWSF) was upgraded to D+ from D on 2/21/2019 due to a noticeable increase in the total return index and volatility index.

Sell 2/6/2019Downgrade
GeneNews Limited (GNWSF) was downgraded to D from D+ on 2/6/2019 due to a decline in the growth index, total return index and volatility index.

Sell 5/17/2018Downgrade
GeneNews Limited (GNWSF) was downgraded to D+ from C- on 5/17/2018 due to a large decline in the total return index, valuation index and growth index. Operating cash flow declined 159.01% from -$367.2 to -$951.1, and total revenue declined 91.53% from $53.1 to $4.5.

Hold 4/4/2018Upgraded
GeneNews Limited (GNWSF) was upgraded to C- from D on 4/4/2018 due to a significant increase in the efficiency index, growth index and solvency index. Operating cash flow increased 56.2% from -$838.3 to -$367.2, earnings per share increased from -$0.0065 to -$0.0033, and the quick ratio increased from 0.02 to 0.03.

Sell 5/12/2017Downgrade
GeneNews Limited (GNWSF) was downgraded to D from D+ on 5/12/2017 due to a major decline in the growth index and volatility index. Earnings per share declined from $0.0129 to -$0.02, EBIT declined 140.31% from -$513.5 to -$1.23M, and total revenue declined 33.22% from $285.7 to $190.8.

Sell 3/31/2017Downgrade
GeneNews Limited (GNWSF) was downgraded to D+ from C- on 3/31/2017 due to a significant decline in the efficiency index, solvency index and valuation index.

Hold 2/1/2017Upgraded
GeneNews Limited (GNWSF) was upgraded to C- from D+ on 2/1/2017 due to an increase in the total return index and volatility index.

Sell 1/11/2017Downgrade
GeneNews Limited (GNWSF) was downgraded to D+ from C- on 1/11/2017 due to a noticeable decline in the total return index.

Hold 12/27/2016Upgraded
GeneNews Limited (GNWSF) was upgraded to C- from D+ on 12/27/2016 due to a noticeable increase in the total return index and valuation index.

Sell 11/11/2016Upgraded
GeneNews Limited (GNWSF) was upgraded to D+ from D on 11/11/2016 due to a significant increase in the efficiency index, total return index and growth index.

Sell 8/12/2016Downgrade
GeneNews Limited (GNWSF) was downgraded to D from D+ on 8/12/2016 due to a significant decline in the efficiency index, solvency index and total return index. The quick ratio declined from 0.07 to 0.01, total capital declined 36.79% from -$1.63M to -$2.24M, and debt to equity increased from -0.58 to -0.55.

Sell 6/24/2016Upgraded
GeneNews Limited (GNWSF) was upgraded to D+ from E+ on 6/24/2016 due to a significant increase in the efficiency index, solvency index and valuation index.

Sell 6/17/2016Downgrade
GeneNews Limited (GNWSF) was downgraded to E+ from C- on 6/17/2016 due to a significant decline in the efficiency index, solvency index and growth index.

Hold 5/27/2016Upgraded
GeneNews Limited (GNWSF) was upgraded to C- from D- on 5/27/2016 due to a significant increase in the efficiency index, total return index and growth index. Total revenue increased 100% from -$903.8 to $0, operating cash flow increased 56.19% from -$754.6 to -$330.6, and EBIT increased 54.18% from -$1.59M to -$729.7.

Sell 3/11/2016Downgrade
GeneNews Limited (GNWSF) was downgraded to D- from D on 3/11/2016 due to a major decline in the total return index, volatility index and solvency index. The quick ratio declined from 0.88 to 0.29.

Sell 8/14/2015Downgrade
GeneNews Limited (GNWSF) was downgraded to D from D+ on 8/14/2015 due to a decline in the efficiency index, solvency index and total return index. The quick ratio declined from 4.07 to 0.88, and total capital declined 8.61% from $2.3M to $2.1M.

Sell 4/21/2015Downgrade
GeneNews Limited (GNWSF) was downgraded to D+ from C- on 4/21/2015 due to a large decline in the total return index and volatility index.

Hold 4/6/2015Upgraded
GeneNews Limited (GNWSF) was upgraded to C- from D+ on 4/6/2015 due to an increase in the volatility index.

Sell 4/2/2015Upgraded
GeneNews Limited (GNWSF) was upgraded to D+ from D on 4/2/2015 due to a large increase in the solvency index, efficiency index and valuation index. Net income increased 143.63% from -$820.6 to -$2M.

Sell 11/21/2014Downgrade
GeneNews Limited (GNWSF) was downgraded to D from C on 11/21/2014 due to a major decline in the efficiency index, volatility index and valuation index. Total capital declined 342.8% from -$1.71M to $4.15M, and net income declined 66.97% from -$2.48M to -$820.6.

Hold 10/23/2014Upgraded
GeneNews Limited (GNWSF) was upgraded to C from C- on 10/23/2014 due to an increase in the total return index.

Hold 8/19/2014Upgraded
GeneNews Limited (GNWSF) was upgraded to C- from D+ on 8/19/2014 due to a noticeable increase in the efficiency index and valuation index. Net income increased 52.19% from -$1.63M to -$2.48M.

Sell 5/29/2014Upgraded
GeneNews Limited (GNWSF) was upgraded to D+ from D on 5/29/2014 due to a significant increase in the volatility index, total return index and growth index. Total revenue increased 422.86% from $35 to $183, and EBIT increased 2.3% from -$738.5 to -$755.5.